Nyxoah was founded in Belgium by serial entrepreneur Robert Taub with the core mission of developing revolutionary bioelectronic neurostimulation treatments for obstructive sleep apnea. Over the years, the company advanced its flagship Genio system through rigorous European clinical trials, secured CE Mark approval, pursued extensive US clinical investigations, and completed an international public listing on both Euronext Brussels and the NASDAQ exchange to fund its commercial expansion.